ZTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zoetis Inc (ZTS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently in a bearish trend, with analysts showing mixed to negative sentiment and limited near-term growth catalysts. While the company's financials show modest growth, the lack of strong innovation and the current valuation do not make it an optimal entry point for long-term investment.
The stock is in a bearish trend with MACD negatively expanding (-0.793), RSI at 24.313 (neutral zone), and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 120.463), with resistance levels at R1: 131.175 and R2: 134.483.
Hedge funds have significantly increased their buying activity (+228.26% last quarter). The company has a strong gross margin (68.96%) and modest YoY financial growth in revenue (+3.02%), net income (+3.79%), and EPS (+6.98%).
Analysts have downgraded the stock multiple times recently, citing a lack of organic growth and an 'innovation air pocket' that could last 1-2 years. The stock has a bearish technical setup, and options data suggests bearish sentiment (high put-call volume ratio of 2.73). Additionally, the recent acquisition of Neogen's animal genomics division has not been well-received by the market, as reflected in a 1.4% drop in share price post-announcement.
In 2025/Q4, Zoetis reported revenue of $2.387 billion (+3.02% YoY), net income of $603 million (+3.79% YoY), EPS of $1.38 (+6.98% YoY), and a gross margin of 68.96% (+1.38% YoY). While these figures indicate modest growth, they are not indicative of strong momentum.
Analysts have downgraded the stock from Buy to Neutral or Hold, with price targets ranging from $131 to $140. The sentiment reflects concerns about limited near-term growth and the lack of significant innovation until 2026.
